Clinical trial · Interventional
Lung Cancer Indicator Detection
NCT02612532CI-TRIAL-00067276LuCIDcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ReCIVA breath sampler | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LuCID
- description
- Standardised exhaled volatile organic compound collection by "ReCIVA" breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)
- interventionNames
- Device: ReCIVA breath sampler
Primary outcomes (1)
- measure
- Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.
- timeFrame
- 2 years
- description
- Diagnostic accuracy of VOC analysis for Lung Cancer diagnosis based on pattern recognition analysis of raw VOC-spectra generated by Lonestar analysis of breath.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Recruitment for these patients will be done from NHS hospitals whom identify or follow-up on patients suspected of having lung cancer.
* Inclusion criteria:
* Older than 18 years at time of consent
* Referred for investigation due to suspicion of lung cancer
* Referral based on suspicious symptoms
* Referral based on suspicious finding on imaging, including CTscan with indeterminate nodule requiring follow-up evaluation.
* Capable of understanding written and/or spoken language
* Able to provide informed consent
* Exclusion criteria:
* (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypo-ventilation, respiratory failure or claustrophobia when wearing the sampling mask
* Participating in a Clinical Trial Investigational Medicinal Product (CTIMP)
* Pulmonary function test with metacholine or beta-2-sympatico mimetic in last 2 hours.
* Any lung biopsy in the past 48 hours
* Currently undergoing anti-cancer treatment for lung cancerReferences
Publications (0)
Data not yet available
No reference posted for this study.